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ABSTRACT 
Alzhiemer’s disease (AD) is an age-old known neurodegenerative disorder caused by the 
formation of insoluble plaques within and around the neurons of the central nervous system 
resulting in lack of emotional and memory response of an individual. Till date there have been 
a variety drugs made available in the market which help combat or regress the pace of the 
symptoms of the disease, but none so-ever formulated commercially to treat the cause of the 
disease.  
One of the most significant causative factors of the disease progression is the failure of the heat 
shock protein Hsp-90 to adequately refold the insoluble Tau protein tangles formed within the 
neuronal cytoplasm, and concurrently not being able to trigger the proteolytic degradation of 
the same. A variety of drug molecules have been hitherto designed and tested for satisfactory 
insilico and invitro inhibition of the Hsp90 protein complex, rendering the cellular system to 
switch to proteasomal degradation pathway towards the tangled Tau elimination. Inhibition of 
C-Terminal of Hsp90α by blocking its ATP binding sites might be used as an effective 
therapeutic approach for the treatment of AD via degradation of Tau proteins.  
In our present work, it was observed that Leu 666, Leu 666 and Leu 694 could possibly be the 
ATP binding sites of Hsp90α CTD. It was also known from the experimental results that among 
the existing drugs, Derrubone showed the best binding affinity (-7.53 kcal/mol) for Hsp90α 
CTD.  
Derrubone, which had proved its mark as the best among inhibitory molecules, has been 
structurally modified resulting in molecular analogues that have basic molecular skeleton of 
the original drug but serve improved ADME and inhibitory properties as against the same. 
Additionally, two previously experimentally synthesized Derrubone analogues developed by 
Blagg et. al. have been analyzed for validation of our recognized ATP binding sites and 
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compared with the newly designed analogues for their inhibitory properties at the recently 
recognized ATP-binding sites of the Hsp-90 molecule. Among the 30 analogues designed and 
tested insilico for various properties such as lipophilicity (AlogP), inhibitory constants (ki), 
binding energy, carcinogenicity, mutagenicity, biodegradability using software viz. Discovery 
Studio 4.0, AutoDock 4.0 and other online tools; Analogue 26 consisting of ether substitution 
at the 5th position of the isoflavon backbone proved a better drug as compared to Derrubone 
and the analogues developed at the laboratory of Blagg et. al, with a binding energy of -10.16 
kcal mol-1 at Leu694 binding site, inhibitory constant of 0.036 µM and lipophilicity of 4.481. 
It was concluded from the data obtained from experimental results that A26 could bind with 
CTD of Hsp90α strongly and result Tau protein degradation which might be considered to be 
a therapeutic approach in AD.   
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1.1 INTRODUCTION 
1.1.1 Introduction to Alzheimer’s Disease 
Alzheimer’s disease (AD) is a type of neurodegenerative disorder, its symptoms worsen as the 
time progresses thereby leading to irreversible intellectual and cognitive impairment, memory 
loss and ultimately to nerve cell death. With time, there are various ongoing researches which 
have given impeccable information about the disease, but so far there had been no cure for the 
disease. AD is not considered as the part of aging, when it occurs in individuals above 60, 
known as Late-onset whereas Early-onset occurs during the mid ages like 40s and 50s, but this 
is quiet uncommon among people [1].  In Earlier times, mentally ill people were considered to 
be insane or thought to be possessed by evil spirits. The treatments that were given to these 
people were very hard, but in the later period of time these people were taken care in the 
hospitals and the researchers began to determine the cause for the disease.  
For understanding AD, it is important to have basic knowledge about the brain. There are 
number of cells present inside the brain, among them, neurons are highly electrically active 
cells which communicate with other nerve cells present within the brain through their dendrites 
and axons.  When the dendrites of one neuron (pre-synaptic neuron) receive signals, they 
generate nerve impulse which travels along a neuron to the axon terminus and release a 
chemical known as neurotransmitter into a small gap known as synapse. From this gap the 
neurotransmitter is received by the receptors present at the boundary of post-synaptic neuron 
and as soon as it enters the interior of neuron it will work according to the received signal [2, 
3]. 
AD mainly disturbs the chemical synapse scheme by disrupting the connection between the 
neurons leading to loss of metabolic activity and cell death. The death of neurons spread widely 
among nerve cells and the region of brain containing the dead neurons starts to shrink leading 
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to brain atrophy. Due to the death of neurons various symptoms can be observed in the patients 
such as mood swings, hallucinations, memory loss, orientation problem etc.  
1.1.2 Causes of AD 
The characteristic features of AD are the presence of two prominent unusual features in the 
brain which are made up of misfolded proteins – amyloid plaques and neurofibrillary tangles 
[4, 5]. These are abundantly present in the region of brain that is necessary for memory. Dr. 
Alois Alzheimer specified that amyloid plaques are formed outside the neurons due to the 
accumulation of amyloid beta-peptides. When normal brain ages, normal quantity of amyloid 
plaques deposit in the brain but in diseased condition the amount of these plaques increases 
than usual. It is unidentified that whether the disease is caused due to the accumulation of the 
amyloid plaques or these plaques are just the by-products of the disease processes.  
1.1.3 Symptoms 
It is believed that Alzheimer’s disease develops in different ways but with many common 
symptoms in every individual and makes it very difficult to predict that how it will affect the 
person. One of the earliest symptom of the disease includes loss of memory but when the 
disease progresses, mood swings, aggression, confusion, long term memory loss etc. develops 
and the diseased person start becoming isolated from family and friends. Gradually, many body 
functions are gone which will ultimately leads to death. As AD can develop without being 
evident for uneven amount of time therefore it can progress undiagnosed for many years. The 
person suffering from Alzheimer’s disease has the life expectancy of maximum seven years 
after getting diagnosed and very few persons can live more than fourteen year after diagnosis 
[6, 7].  
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1.1.4 Diagnosis 
The initial diagnosis of Alzheimer’s disease includes a series of tests and analysis to confirm 
the condition of the body including the brain. These tests include imaging techniques such as 
MRI, CT scan, PET scan which can detect neurological activity within the brain as well as the 
presence of any clump or an aberrant mass which may be indicative of amyloid plaques. The 
PET scan specially maps the regional activity of the brain through which we can confirm any 
abnormal loss of activity in the characteristic AD region such as the hippocampus.  PET scan 
helps explorers to better diagnose the progression of Alzheimer's disease in different 
peripheries of the brain. Nowadays, Doctors and scientists are obtaining 3-D images of the 
brain by combining both PET (positron emission tomography) scan with MRI (Magnetic 
resonance imaging) to measure the rate different regions of the brain uses, deposits and 
metabolize certain chemicals.  This has become possible with the advance of a radiolabeled 
compound called Pittsburgh Compound B (PiB). This PiB can bind to beta-amyloid plaques in 
the brain and it can be imaged using PET scans. A series of blood tests are also carried out to 
detect anomalous proteins in the vascular system. These tests are also followed by various 
cycles of psychological counselling of both the patient and kin to confirm any behavioural 
changes over the past period of time [8, 9, 10]. 
1.1.5 Current treatments of AD 
Alzheimer’s disease is regarded as an incurable condition, regardless of which many of the 
drugs are available in the market today which are prescribed associated with this disease, treat 
the symptoms rather than the disease itself. Lately, there are drugs that are being used to treat 
various symptoms of AD such as cholinesterase inhibitors, NMDA receptor antagonists, 
Antihypertensives, Antidepressants, Selective Serotonin Reuptake Inhibitors, Monoamine 
Oxidase (MAO) Inhibitors and anti-diabetes drugs. 
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 Cholinesterase inhibitors such as tacrine, rivastigmine, galantamine, donepezil etc block the 
active sites of AChesterase thereby preventing the degradation of acetylcholine and results in 
efficient signal transduction [11]. These drugs have high toxicity and acute side-effects such as 
hallucinations, confusion, fatigue, dizziness, nausea etc. Hence, it is a requirement of new 
researches to come up with a drug with least side effects and one which treats the disease as a 
whole rather than just the symptoms [12]. 
 NMDA receptor antagonist like memantine has been approved for the treatment of moderate 
to severe AD as the clinical trials showed improvements with and without cholinesterase 
inhibitor [13, 14].  
Antihypertensives like β-blockers and Hydrochlorothiazide are observed to decrease the 
progression of AD. Unluckily, the studies which are related to hydrochlorothiazide are all 
concerned with the reduction of blood pressure upon progression of dementia rather than to 
detect anti-dementia MOA [15].  
Antidepressant such as Amitriptyline is used to treat depression, migraine and neuropathic 
pain. In studies, it was observed from different cellular models that this drug binds to TrkA and 
TrkB which can prevent apoptosis or death of nerve calls (brain cells). Although, in this 
treatment with the decrease in toxic Aβ dimer there is an increase of non-toxic Aβ monomer 
thereby increasing the total Aβ in animal models [16].  
Selective Serotonin Reuptake Inhibitors such as fluoxetine, Paroxetine and desvenlafaxine 
showed a decrease in levels of Aβ plaques in patients who had been taking these drugs [17]. 
Paroxetine is a drug that had been known to increase brain derived neurotrophic growth factor 
and reduce the levels of Aβ and p-Tau (phosphorylated Tau) thereby conserving the cognitive 
function in AD mouse models [18].  
Monoamine Oxidase (MAO) Inhibitors like Selegeline and rasagiline are known for their 
neuroprotective property in both cellular and animal models. The mode of action of these is 
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based on preventing apoptosis of nerve cells by stopping the activation of caspase 3. Rasagiline 
is advantageous over selegeline as it does not have toxic metabolism like selegeline [19, 20].  
Anti-diabetes drug like Metformin is used to treat type II diabetes mellitus when went through 
an experimental observations in AD models have produced mixed results. Upon administration 
of metformin alone, the generation of Aβ found to be increased by upregulating β-secretase 1. 
However, these levels were found to be reduced when the drug was administered along with 
Insulin. When metformin was administered in an insulin-resistant neuron model, it prevented 
neuropathological and molecular features of AD [21, 22]. 
1.1.6 Role of Hsp90α in the treatment of AD 
 Heat shock protein 90 plays a significant role in folding, stabilizing, activating and maintaining 
the conformational integrity of its client proteins like dcd4, B-Raf, Her2 etc through its ATPase 
activity. Hsp90α is a homodimer where each monomer consists of three different conserved 
domains namely a 25kDa N-Terminal domain (NTD) which contains a nucleotide binding site, 
35kDa Middle domain (MD) which has client protein binding site and 12kDa C-Terminal 
domain (CTD) having a ATP binding and dimerization site (fig 1). Treatment of AD through 
drugs interacting with molecular chaperones focuses on the inhibition of Hsp90α thereby 
initiating the cascade of the degradation pathway rather than refolding of tangled HP-Tau 
proteins. One such mechanism to carry out this process includes the blockage of ATP binding 
sites at the CTD of the molecular chaperone and hence leads to the retardation of disease 
progression. As it is a well-known fact that Tau pathology is closely associated with the 
neuronal loss due to its ability to cause neurotoxicity. Therefore, Targeting Tau tangles would 
be advantageous to be used as a therapeutic strategy for treating AD.  
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Figure 1: Structure of Hsp90α. 
The use of these inhibitors for blocking Hsp90α could be a novel approach for the treatment of 
brain maladies like AD. Till date, there have been a number of experiments carried out which 
describes the role of Hsp90α inhibition for the treatment of AD [23, 24, 25]. Various inhibitors 
such as Geldanamycin (GD), 17AAG, 17DMAG etc of Hsp90α NTD have been identified but 
they have few drawbacks associated with them for which they could be used for the treatment 
of AD [26, 27, 28]. Due to the problems associated with the NTD inhibitors, various CTD 
inhibitors came into existence such as Novobiocin, clorobiocin, Derrubone etc [29-33].  
Derrubone is a prenylated flavonoid which was isolated from a tree named Derris robusta [34]. 
Various In-vitro studies has determined Derrubone as a CTD inhibitor of Hsp90α which 
exhibits a novel mechanism of its inhibition by obstructing the ATPase activity of NTD and 
altering the client protein binding to MD through conformational changes in the protein 
structure. Furthermore, it was predicted that Derrubone could strongly bind to the CTD of 
Hsp90α and lead to Tau protein degradation which can be a therapeutic approach for the 
treatment of AD.  
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1.1.7 Bioinformatics and Computational Biology 
Bioinformatics tools help us in a large way to examine and evaluate various biological 
processes which are otherwise hard to evaluate in-vitro or in-situ such as drug designing, 
evolutionary computation, numerical programing of enzymatic processes etc. Bioinformatics 
is an interdisciplinary branch of science that deals with drug designing processes. It has the 
potential to accelerate the process of drug discovery thereby reducing the cost of the process 
and giving different methods of designing a novel drug. Molecular docking is the most 
commonly used method for the identification and designing of novel drugs. It involves docking 
of the drug molecule to its biological target and the binding site for the drug is its site of action 
which gives the pharmaceutical effect of the drug. In molecular docking, the protein and the 
ligand are allowed to bind in a 3D space and give the binding energies and the inhibition 
constant value of the drugs. There are various software which can be used for molecular 
docking experiments after the retrieval of protein structure and drug molecule from online 
databases. The advancement in computational biology approaches has led to the development 
in drug discovery and helps the pharmaceutical sector progress towards better medical facilities 
and provide better health care.  
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1.2 OBJECTIVES 
 Retreival of 3-D structure of C-Terminal domain of Hsp90α. 
 Identification of possible ATP-binding sites of Hsp90α in the CTD using various 
methods and softwares.  
 Calculation of binding affinities of  various Hsp90-CTD inhibitors by performing 
molecular docking study at the determined ATP binding sites using AutoDock 4.0 
software  
 Development of novel analogue of Derrubone which can bind to the previously 
identified ATP binding sites of Hsp90α CTD thereby modifying its binding affinity, 
lipophilicity, water solubility and minimizing its Inhibition constant.  
 The ADME and toxicity studies using Discovery Studio 4.0 software. 
 Molecular docking of the analogues against Hsp90α CTD using Autodock 4.0 and 
the  comparison of binding energies and inhibition constant to obtain a novel 
inhibitor of CTD Hsp90α. 
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REVIEW OF LITERATURE 
2.1 Alzheimer’s Disease 
Dr. Alois Alzheimer, who was a German neurologist, discovered Alzheimer’s disease in 1906 
after examining the brain of 51 year old patient who suffered from depression, dementia, 
paranoia, hallucinations etc, with peculiar formations in the brain (amyloid plaques and 
neurofibrillary tangles). It is believed that an urgent need of strategies to treat AD is required 
as it is highly spreading and largely devastating [5].  
The starting material for the formation of amyloid plaques is the Amyloid Precursor Proteins 
(APP) which is tethered to the cell membrane. There are enzymes present in cellular 
compartments like alpha-secretase, beta-secretase, and gamma-secretase which cleave APP 
into discrete fragments. The cleavage of APP can proceed in two different types of pathways 
which can have two different consequences for the neuron i.e. favourable pathway and 
unfavourable pathway. In the harmful pathway, oligomers are formed due to the sticking of 
three, four or more beta amyloid plaques, resulting in enlargement of oligomers and formation 
of protofibrils and fibrils. Further, different proteins and other cellular materials also get 
attached to these insoluble entities and results in the occurrence of beta amyloid plaques [35, 
36].  
Another characteristic of AD is the formation of neurofibrillary tangles. The transport of 
nutrients and vesicles containing the neurotransmitters by healthy neurons is done through 
microtubules. These microtubules are stabilized by Tau proteins which have few phosphate 
molecules attached to them. GSK-3β is the most important enzyme which plays its role in 
phosphorylating Tau proteins either in normal or diseased condition. In AD the major 
component of tangles are Tau proteins and these proteins become three to four fold more 
phosphorylated than in normal brain of an individual. The HP-Tau leads to the reduction in 
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binding ability of MTs leading to its disorganization, subsequently Tau proteins form 
aggregates in the form of NFTs within the cytoplasm, which cause damages in the neuronal 
transport pathway. In the diseased condition, large number of phosphate molecules gets 
attached to the Tau protein and this hyperphosphorylation disengages the Tau from the 
microtubules. These Tau proteins cling with other Tau threads resulting in the formation of 
tangles inside the nerve cell. This causes the disintegration of microtubules and damages the 
transport pathway of the neurons by disrupting the communication between the neurons [37, 
38]. 
AD is due to mutations that occur in APP (amyloid precursor proteins) and PS1 (presenilin). 
The main cause for this is polymorphism of APOE (apolipoprotein) gene. APOE is produced 
by microglial and astrocytes in brain cells and they have their role in clearance of amyloid 
present extracellular. Thus if the mutations occurs in APOE it reduces their efficiency to clear 
the Aβ peptide and result in accumulation of these leading to the progression of the disease. 
Later, it was revealed that upon reducing the amount of amyloid does not stop or halt the 
disease. Another approach of using a drug ‘FLURIZAN’ (ϒ secretase modulator) which 
inhibits PS1 was also remain ineffective in preventing the Aβ production. Hence, alternate 
stratergy was required which targeted on another cause of the disease that is Tau protein 
aggregation into tangles. Microtubule associated protein Tau (MAPT) gene was found to cause 
disease. It was found that Tau is capable of causing neurotoxicity therefore neuron loss was 
considered to be closely related to tangle pathology. Finally, Targeting Tau tangles was 
considered to be more effective strategy than anti- Aβ therapies [39].  
2.2 Hsp90α and AD 
The formation of HP-Tau can either be directed towards refolding, de-phosphorylation or 
proteasomal degradation when all other mechanisms fail [fig. 2]. In diseased condition, it is 
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supposed that these mechanisms become inactive and results in NFTs [40, 41]. HP-Tau not 
only has distorted conformation but it also has increased affinity for molecular chaperones like 
Hsp90α. Hence, Tau clearance can be achieved by developing the strategies which can target 
Hsp90α and related co-chaperones [42].  
Figure 2: Pathway describing the stabilization of neuronal microtubules with the help of Tau protein. The 
activation of Tau proteins occur by their phosphorylation and their hyperphosphorylation can either lead 
to its dephosphorylation assisted by Hsp27, trigger to proteasomal degradation by Hsp90/70-CHIP complex 
or their deposition occurs as NFTs leading to neuronal atrophies [ Khalid S and Paul S. Medical hypotheses 
2014]. 
 
Hsp90α is a molecular chaperone which is inducibly expressed during the stress conditions like 
nutrient deprivation, malignancy, exposure to toxins etc. and is involved in the refolding of 
unfolded proteins with the help of co-chaperones like p23, PP5 etc. [43] or can otherwise 
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initiate the proteasomal degradation pathway. There are about 100 client proteins which have 
been identified as Hsp90-dependent client proteins [44]. The connection of Hsp90α with 
neurodegenerative diseases is basically due to its capability to refold aggregated proteins like 
HP-Tau proteins [45]. Therefore, it has been recognized that HP-Tau acts as a client protein 
for Hsp90α [46].  Drugs which bind to the ATP binding sites present in NTD and CTD of 
Hsp90α can inhibit the same thereby initiating the proteasomal degradation of HP-Tau in AD 
(fig. 3).  
During the preliminary stage, when ATP is not bound to Hsp90α, NTD remains in an open 
conformation and the charged regions mask the CTD ATP-Binding site. Upon binding of ATP 
to NTD of Hsp90α, its conformational modifications occur and it exposes the ATP binding site 
of CTD. The binding of ATP to CTD follows with allosteric changes, causing the 
conformational readjustments rather than stimulating the ATPase activity [47, 48]. The binding 
of ATP to CTD leads to the dimerization of NTD along with the attachment of client proteins 
like Tau to MD which is assisted by Hsp70/Hsp40 complex. Subsequently, AHA1 and co-
chaperones like p23, PP5 assists in hydrolysis of ATP and refolding of client protein, 
respectively and the NTD goes back to its open conformation state thereby releasing the folded 
Tau protein and ADP.  
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Figure 3: Mechanism of Tau tangles repair by Hsp90α. The molecular chaperone can subject the hyper-
phosphorylated Tau tangles to refolding or proteasomal degradation depending on the attachment of ATP. 
ATP activation of Hsp90α renders the Tau protein to refolding process and the inactivation of the same 
leads to degradation of the protein through ubiquitination by CHIP protein [Khalid S and Paul S. Medical 
hypotheses 2014]. 
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In the treatment of AD, when the inhibitors are allowed to bind to the ATP binding site of 
Hsp90α rather than ATP itself, the complex of HP-Tau protein with Hsp70/Hsp40 interacts 
with Hsp90α thereby allowing the recruitment of CHIP and directing the HP-Tau protein to 
proteasomal degradation [49, 50, 51]. There exist various drugs which can inhibit Hsp90α by 
blocking the ATP binding site of NTD, obstructing the client protein binding site of MD or by 
inhibiting CTD [52, 53]. The Hsp90α inhibitors bind to these domains and block its activity to 
stabilize or refold client proteins which are thereby degraded by Ubiquitin-proteasome pathway 
[54, 55].  The folding mechanism of client proteins by Hsp90α is carried out upon dimerization 
of CTD which is followed by the hydrolysis of ATP molecules. Hence, it is believed that the 
inhibition of CTD of Hsp90α might be a significant approach in various neurodegenerative 
diseases like Alzheimer’s disease (AD) [40].  The binding of ATP has also been reported in 
the C-Terminal domain of Hsp90α [39]. 
2.3 Hsp90α Inhibitors 
GD has very good binding affinity with Hsp90α but it shows poor water solubility and high 
hepatoxicity which later lead to the development of its soluble derivatives namely 17AAG (17-
N-Allylamino-17-demethoxygeldanamycin) and 17DMAG (17-Dimethylaminoethylamino-
17-demethoxygeldanamycin) [58]. There are various drawbacks associated with these 
derivatives such that 17AAG, despite being less toxic, has less binding affinity than GD for 
Hsp90α [26, 27] and 17DMAG  has problems associated with drug clearance due to limited 
metabolism and it could not be used for prolonged period [59, 60].  
To resolve the problems associated with NTD drugs, various CTD binding drugs such as 
Novobiocin, EGCG (Epigallocatechingallate), Derrubone, Clorobiocin etc. were also 
discovered later [29-33]. Novobiocin which was observed to bind CTD nucleotide binding site 
also showed very weak appearance of inhibition in cellular-based assays (IC50 ca. 500–700 
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μM) when compared to the inhibitors of NTD (IC50 < 100 nM) and it also has limited water 
solubility [61, 62]. As the folding mechanism of client proteins by Hsp90α is carried out upon 
dimerization of CTD which is followed by the hydrolysis of ATP molecules. Therefore, the 
inhibition of CTD of Hsp90α is being a significant approach in various neurodegenerative 
diseases like Alzheimer’s disease (AD) [56].  The binding of ATP has also been reported in 
the C-Terminal domain of Hsp90α [57]. 
The crystal structure of Hsp90α CTD does not currently exist in the databases. The prokaryotic 
Hsp90α has been found to have 40-60% similarity with human Hsp90α (hHSP90α) [63, 64]. It 
has been known that the truncated CTD of Hsp90α could bind molecules with comparable 
affinity as that of fully intact Hsp90α [65]. 
2.4 Properties of a CNS Drug required to cross BBB 
As AD is a brain malady, it is required that the drug should pass through the blood brain barrier 
(BBB), that is made up of tight junctions between the epithelial cells surrounding the αbrain 
tissue. The central nervous system (CNS) drugs should satisfy various properties of 
pharmacokinetic profile for crossing the BBB for which a set of rules are derived from about 
1500 drugs, which includes 
 lipophilicity (AlogP<5) : AlogP of a drug is the optimized octonal/water partition 
coefficient, which gives the measure of its lipophilicity that is an important factor for 
its oral absorption owing to its ability to penetrate through the cell membrane of the 
epithelia. Hydrophilic and lipophilic values of a drug which increase beyond a certain 
value are not considered ideal for CNS drugs. The drugs must be polar to be soluble in 
water, fatty to be able to cross BBB to avoid rapid excretion, weak bases are preferable 
and it must have lipophillic and hydrophilic character. AlogP of a drug is the optimized 
octonal/water partition coefficient, which gives the measure of its lipophilicity that is 
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an important factor for its oral absorption owing to its ability to penetrate through the 
cell membrane of the epithelia. Hydrophilic and lipophilic values of a drug which 
increase beyond a certain value are not considered ideal for CNS drugs. The drugs must 
be polar to be soluble in water, fatty to be able to cross BBB to avoid rapid excretion, 
weak bases are preferable and it must have lipophillic and hydrophilic character. 
 Polar surface area (PSA<60-90 Å2): Polar surface area denoted as Å2, is the surface 
area that is occupied by oxygen and nitrogen atoms and the polar hydrogens that are 
attached to them. It gives the hydrogen bonding capacity and polarity of a drug. Many 
investigators has been used PSA as a predictor for BBB penetration [67, 68]. 
 Molecular weight (<450): this parameter is considered to be critical for BBB 
penetration. The molecular weight of CNS drugs is less than that of other therapeutic 
drugs. 
 Number of rotatable bonds (<8): Rotatable bonds give the molecular flexibility of a 
drug and it is known that the CNS drugs have significantly fewer rotatable bonds as 
compared to the non-CNS drugs.  
 Hydrogen bond donors (<3) and acceptors (<7): are responsible for the formation of 
hydrogen bonds between the drug and the protein molecule [66]. 
The optimization of the drug candidate with respect to its absorption, distribution, metabolism 
and excretion (ADME) is the most important part of drug designing thereby defining the 
therapeutic efficiency and character of a drug [67, 68, 69]. 
Absorption property for a particular compound is required when it not given to the patient 
directly into the bloodstream through intravenous administration.  Hence, it is important for a 
drug that it should be transported to the circulation system from the site of administration, as it 
is considered to be absorbed when it is has entered the blood circulation. The absorption of 
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drugs solely depend upon two factors i.e. lipophilicity and solubility of a drug molecule. 
Factors like chemical instability, poor compound solubility, inability to permeate intestinal 
wall could lead to poor absorption.  
Distribution property of a drug is required once it has entered the blood stream. The drug is 
allowed to get distributed across the body after absorption. This property of a drug could not 
be calculated directly therefore it is given by a relationship between the concentrations of drug 
present across the body to the amount of drug present in the blood for distribution at the same 
time. Factors affecting distribution are the poor blood flow rate, molecular size, polarity etc.  
Metabolism of a drug is required for making the drug more soluble in water by breaking it into 
small metabolites, so that it could be excreted out easily from the body. The oxidation-
reduction, hydrolysis and conjugation are the reactions which are involved in the metabolism 
of a drug candidate. The enzymes that are required for the metabolism of a drug are mostly 
located in the liver eg Cytochrome P40 enzyme for oxidative metabolism.  
Excretion is another very important property required by a drug for their removal from the 
body, which can be achieved by kidney (urine), feces (bilary excretion) or lungs (anaesthetic 
gases). Other routes of elimination include the liver, sweat, and saliva [70]. 
The structure activity relationship (SAR) of Derrubone has led to the development of analogues 
which could give better binding affinity with lesser inhibition constant (ki) than DB [71] along 
with better lipophilicity and aqueous solubility. The solubility of the drug could be increased 
by addition of polar groups like alchohol, amide, amine, carboxylic acids etc as they are capable 
of making strong intermolecular forces of attraction like hydrogen bonds. The lipophilicity of 
a drug can be enhanced by increasing the length of the alkyl chain attached to the basic structure 
of the drug. 
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3.1 MATERIALS 
3.1.1 Tools and bioinformatics softwares used: 
 Protein Data Bank (www.rcsb.org/pdb/home/home.do) 
 Pubchem (pubchem.ncbi.nlm.nih.gov)  
 PRODRG Server (davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg) 
 PHYRE 2 Server (Protein Homology/analogY Recognition Engine) 
 ArgusLabs 
 Chimera 1.6.1 
 Open babel GUI software   
 ATPint 
 Ligplot+ v1.4.5  
 Protein Hydrophobicity Plot (www.vivo.colostate.edu/molkit/hydropathy/) 
 Autodock 4.0  
 Hex 6.3 
 ACD/ChemSketch 
 ChemBioDraw Ultra 13.0 
 MedChem Designer 
 Discovery studio 4.0  
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3.2 METHOLOGY 
3.2.1 Retrieval of 3D structure of C-terminal Hsp90α and drugs 
The present experiments have been carried out by utilizing the 3-D structures that are retrieved 
from PHYRE2 server. The server prepared the structure from homology modelling of 
prokaryotic Hsp90α which is believed to be 40–60% similar to hHsp90α (human). Following 
are the steps involved in the retrieval of the 3D structure of Hsp90α CTD: 
The URL www.sbg.bio.ic.ac.uk/phyre2/ was opened for PHYRE2 Server. 
The E-Mail address and job description is given in the space provided. 
The residues from 628-732 are pasted in the amino acid sequence box followed by the 
running of normal PHYRE2 Search. 
 
The result obtained from the PHYRE 2 server is sent to the provided E-Mail address 
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The 3D structures of drugs or Hsp90-inhibitors were retrieved from PubChem followed by 
their energy minimization in PRODRG server. The steps involved in obtaining the structures 
of the inhibitors are mentioned below: 
After opening the URL pubchem.ncbi.nlm.nih.gov/, the compound name was entered 
in the space provided. 
For obtaining the 3D conformation of the drug, 3D SDF display was opened and 
copied. 
 
PRODRG URL davapc1.bioch.dundee.ac.uk/cgi-in/prodrg/ was opened and the 3D  
SDF display coordinates obtained from PubChem were pasted in it. 
With charges keeping full, PRODRG was run. 
 
Finally, only the PDB file (polar hydrogens) box was selected from the output and 
saved in .pdb file format in word pad. 
 
3D structures of drugs such Novobiocin, Clorobiocin, Derrubone, EGCG etc were 
obtained from PubChem server. 
.  
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3.2.2 Identification of ATP binding sites in C-Terminal domain (CTD) of Hsp90α using  
various software 
3.2.2.1 ATPint 
 it is an online Server used for predicting the ATP binding sites from aprotein sequence of a 
molecule. The server works with the help of Support Vector Machine (SVM) and Position-
specific scoring matrices (PSSM) generated by psi-BLAST. The following are the steps 
involved in the prediction: 
URL www.imtech.res.in/raghava/atpint/submit.html was opened 
The sequence name along with the E-Mail address was entered 
Amino acid sequence from 628-732 amino acids of Hsp90α CTD was input in FASTA 
format 
 
The software was run and the results were sent to the E-Mail ID provided. 
3.2.2.2 CAST P calculation 
It is also an online server that is used to predict the binding sites of a protein molecule. 
According to this software the possibility of ATP binding sites is expected to be present in the 
largest cavity or pocket of the input 3-D structure of Hsp90α. The steps involved in determining 
the active sites are Firstly, sts-fw.bioengr.uic.edu/castp/calculation.php browser was opened 
and the protein structure was input in .pdb file format. 
3.2.2.3 Hex 6.3 
Hex 6.3 is molecular docking software which gives the value of binding energy upon 
interaction of receptor and ligand molecules. The binding energies results obtained from the 
software is calculated upon addition of all the intermolecular forces that could be possibly 
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occurring between the receptor and the drug molecule. Rigid as well as flexible docking could 
be performed using the software. In the process of obtaining the binding energies, a grid box 
is created on a named atom of protein molecule i.e the recognized ATP binding site, on which 
the drug molecule interact followed by docking. In the software, the 3-D structure Hsp90α 
CTD and various drugs were input in the .pdb format. Docking option was selected from the 
control tab and run. 
3.2.2.4 LigPlot+ v.1.4.5 
It is used to obtain the 2D images of the docked complexes by providing the interacting residues 
and bonds that are present in the vicinity of the binding site of ligand and protein molecule. 
The 3D structure of protein-ligand docked molecule (Hsp90α CTD-drug) is input in the 
software in .pdb file format. In the LigPlot analysis, the interpretation of the result obtained 
was done by using the following information.  
 The residues which were denoted by red coloured arc showed the hydrophobic residues 
of the protein molecule that interacted with the drug molecule. 
 The oxygen, carbon and nitrogen atoms were represented by red, black and blue color 
spheres, respectively, of the drug molecule whereas the purple colored lines represented 
the bonds that were present within the drug molecule. 
 Blue colour bonds presented between the drug and the protein molecule were the 
external bonds. 
 Bonds which were coloured green indicated the hydrogen bonds that were formed 
between the drug and protein. 
 
 
 
 
26 
 
3.2.2.5 Protein hydrophobicity plots 
The software predicts the hydrophobic character of input protein sequence. This program 
utilizes use of two types of scales; the Kyte-Doolittle scale which indicates the hydrophobic 
amino acids, and the Hopp-Woods scale that gives the hydrophilic residues. The current work 
utilizes the Kyte-Doolittle scale with window size set to 19, which displays the most 
hydrophobic residues in the Hsp90α CTD input sequence. 
3.2.3 Molecular docking by AutoDock 4.0 software 
Molecular docking experiments were carried out using Autodock 4.0 which provided the 
binding affinity of Hsp90α along with the inhibition constant with various analogues. The 
software is based on Lamarckian Genetic Algorithm (LGA) giving the lowest energy of the 
system for becoming stable. In the present work, the Autodock 4.0 is used for docking of 
various CTD drugs and newly designed analogues of Derrubone against Hsp90α CTD to find 
out the best binding inhibitor with smallest value of inhibition constant.  
The Hsp90α CTD and the energy minimized drug were docked using the software 
AUTODOCK 4.0 through the following steps:  
a) Protein target :  
i. File -> Read molecule -> Hsp90α 
ii. Edit -> Hydrogens -> Add Polar only 
iii. Edit -> charges -> Add kollmann charges 
iv. Edit -> atoms -> Assign AD4 type 
v. File -> saved in Hsp90α.pdbqt format 
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b) Ligand file : 
i. Ligand -> Input Molecule -> Read Molecule 
ii.  Ligand -> torsion tree -> choose root (manual selection of root atom) 
iii.  Ligand -> torsion tree -> detect root (automatic detection of the root 
that provides the smallest largest subtree). 
iv. Ligand -> output -> save as drug-name.pdbqt format 
c) To prepare macromolecule file : 
i. Grid -> Macromolecule -> Macromolecule target (Hsp90α) 
ii. Grid -> Set Map Types -> Choose Ligand -> selected Ligand (drugs) 
iii. Grid -> Grid Box (in the Grid Options Widget the active site for ATP 
binding was selected to centre the grid box on the active site and the 
number of points in each dimension were adjusted to 60). 
iv.  Close saving current. 
v. Grid -> output -> save as Hsp90α.gpf 
d) Autogrid  
i. Run -> Run AutoGrid. The Run AutoGrid widget opened in which 
Program Pathname (the location of the autogrid3 executable) and 
Parameter Filename (Hsp90α.gpf file) was specified. Log Filename 
will be specified in Hsp90α.glg format automatically (selecting a gpf 
creates a possible related name for the glg). 
ii. Launch  
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e) Prepare docking parameters : 
i. Docking -> Macromolecule -> Rigid Filename (Hsp90α) 
ii. Docking -> Set Ligand Parameters -> Choose Ligand (drug) 
iii. Docking -> Set Search Parameters -> Genetic Algorithm Parameters 
iv. Docking -> output -> Lamarckian Genetic Algorithm (LGA). Save in 
Hsp90α.dpf. 
f) AUTODOCK : 
i. Run -> Run AutoDock. This Opened the Run AutoDock widget in 
which program Pathname (the location of the autodock4 executable) 
and Parameter Filename was specified (Hsp90α.dpf file format). Log 
Filename will be specified automatically in Hsp90α.dlg format 
(Selecting a dpf creates a possible related name for the dlg). 
ii. Launch 
g) Obtaining rmsd value and inhibitor constant: open the Hsp90α.dlg file in 
word pad and copy the atoms corresponding to the highest binding energy and 
paste it in the end of cleaned protein (Hsp90α) text file. Save the word file in 
unicode text document as Hsp90α.pdb. Further the Hsp90α.pdb was opened in 
Chimera software for visualization of the hydrogen bonds. 
h) Visualization of hydrogen bonds : 
Open -> chimera 
Select -> residue -> drug 
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Action -> focus 
Tools -> stucture analysis -> find H-bonds 
This will give all the number of hydrogen bonds formed between the drug and 
the protein (Hsp90α) along with the bond length. Residues forming these 
bonds can also be known through this software. 
The picture is then copied using the print screen option and paste in paint to 
crop and save the image in .jpeg or .png format.   
3.2.4 Design of Derrubone analogues 
The designing of the analogues of Derrubone was carried out using ACD/Labs ChemSketch 
software (ACD/Structure Elucidator, version 12.01, Advanced Chemistry Development, Inc., 
Toronto, ON, Canada, www.acdlabs.com, 2014). The designing of analogues was carried out 
taking into account the properties such as lipophilicity and solubility. The solubility of the 
analogues was improved by adding functional groups like R–OH, R-COOH, R-COO-R’, R-
CO, R-NH2 etc. whereas the lipophilicity was enhanced by groups such as R-O-R’ and by 
increasing the length of alkyl chain. 
3.2.5 ADME and Toxicity Studies of Derrubone Analogues 
The computer aided ADME studies and toxicity studies have been done by using the software 
Accelrys Discovery Studio 4.0 Software. The molecular structure of the query compound 
(Analogues prepared) is input in Mol file format. The investigation is solely based on the 
chemical structure of a compound assisted in determining the BBB penetration, polar surface 
area, aqueous solubility, human intestinal absorption (HIA) etc for a specified set of drug 
candidates. ADME-Plot is a 2D graph plotted against Alogp98 vs. PSA. The graph consists of 
ellipses which are derived from about 800 drugs that can enter CNS after their oral 
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administration and they show the regions where the compound is well absorbed [Egan and 
Lauri, 2002]. There is no prediction made for the compounds that fall outside the 95% and 99% 
confidence ellipses. From the studies, it is known that the candidate will fall within the 95% 
ellipse region if it is found to be 95% of the well absorbed compounds whereas the 99% of the 
well absorbed compounds will fall in the 99% ellipse. This PSA_2D vs AlogP98 graph predicts 
the penetration of BBB as well as the 95% and 99% confidence ellipses of the compound after 
the oral administration. In BBB, the ellipses are not similar to those of human intestinal 
absorption but they have equivalent interpretation. TOPKAT (Toxicity Prediction Komputer 
Assisted Technology) study determines toxicity based on the 2-D structure of a compound. It 
evaluates the Rodent Carcinogenicity, Mutagenicity (Ames test), Aerobic Biodegradability and 
Skin irritation. In the current study, the ADME and toxicity profiles of Derrubone and its 
analogues were carried out to determine a novel inhibitor which can inhibit Hsp90α and could 
be used as a therapeutic drug for treating AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
31 
 
 
 
 
 
 
CHAPTER 4 
RESULTS AND 
DISCUSSION 
 
 
 
 
 
 
 
32 
 
RESULTS AND DISCUSSION 
4.1 Identification of ATP binding sites on C-Terminal domain of Hsp90α 
The ATP binding site of the CTD of Hsp90α is not known; hence we predicted the possible 
ATP binding sites present in this domain using various online servers and. From ATPint 
software, we obtained Leucine(Leu) 694 as an ATP interacting residue of the CTD of Hsp90α. 
The validation of the result obtained from from ATPint, CastP calculation was done. From the 
result of CastP, it was observed that Leu 694 and Leu 665 were present in the largest binding 
pocket of Hsp90α CTD (fig. 4). 
 
Figure 4: CastP Calculation showing the presence of Leucine 694 (66) and Leucine 665 (37) in the largest 
binding pocket of Hsp90α. 
Furthermore, for validation Hex 6.3 was used for performing molecular docking experiments 
of novobiocin and ATP molecule against CTD Hsp90α. The docked results obtained from the 
software were analysed using LigPlot+ 1.4.5. Software (fig. 5a and 5b). The residues denoted 
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by red coloured arc are the hydrophobic residues of Hsp90α that are interacting with the ATP 
and drug molecule, respectively. Red, blue and black colour spheres indicate the oxygen, 
nitrogen and carbon atoms, respectively, of the ligand molecule whereas the bonds are 
represented by purple coloured present within the drug candidate. External bonds between the 
drug and Hsp90α are represented by blue colour. The hydrogen Bonds are represented by green 
colour that are formed between the drug and Hsp90α. From Ligplot analysis, it was known that 
both ATP and Novobiocin were found to be interacting with Leu694 which was previously 
validated by ATPint and CastP calculation. The bonds formed and the interacting residues of 
Hsp90α CTD with Novobiocin and ATP were observed to be identical. These results further 
validated the hypothesis that Leu 694 could be the binding residue for ATP along with two 
other hydrophobic residues Leu 665 and Leu 666. As it is a well-known fact, that the ATP and 
various other ATP binding site-inhibitors bind to hydrophobic and non-polar residues in the 
region [72].   
 
Figure 5a. Ligplot analysis showing the interaction of Hsp90α CTD residues with different ligands (i) 
ATP and (ii) novobiocin. 
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Furthermore, when Hydrophobicity plot was acquired from the software, it was observed that 
residues from 656 to 668 in CTD of Hsp90α falls under the hydrophobic region of the plot 
and further, it was observed that our  previously determined sites Leu665 and Leu 666 comes 
in that hydrophobic region (fig. 6) 
 
Figure 6: Hydropathicity plots showing the hydrophobic regions of Hsp90α CTD. 
4.2 Docking of Hsp90α CTD with its existing inhibitors 
Autodock 4.0 software was used for molecular docking experiments in order to obtain the 
binding affinities of various drugs and their inhibition constants against Hsp90α.  The 
experiment was conducted by docking various existing CTD inhibitors on the previously 
recognized ATP interacting sites i.e Leu 665, Leu 666 and Leu 694, respectively. The binding 
energies and the Inhibition constants values obtained from the above experiment are tabulated 
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in Table 1. The results generated from docking experiments clearly showed that Derrubone 
demonstrates lowest binding energy and the inhibition constant for all the three sites of ATP 
interaction; followed by Novobiocin, Clorobiocin and EGCG. Further, Derrubone had the best 
binding energy and inhibition constant value at Leu 666 (-7.53 kcal/mol and 3.04µm) in 
comparison to Leu 665 (-7.20 kcal/mol and 5.31µm) and Leu 694 (-6.67 kcal/mol and 
12.96µm). 
Table 1: Docking of Hsp90α CTD with ATP and various inhibitors at three different ATP binding sites on 
Hsp90α CTD. 
 
 
4.1.3 Docking of Hsp90α CTD with Derrubone 
As it was analyzed from previous experiments that Leu 665, Leu 666 and Leu 694 could be 
best binding sites of Hsp90α for Derrubone. Further, the docking experiment was performed 
using Hex 6.3 between Derrubone and Hsp90α to validate the results obtained from previous 
experiments. This experiment was followed by LigPlot+ v.1.4.5 analysis  to validate that 
whether our drug interacts with these sites or elsewhere other than the site of interest. From the 
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(ki) (µm) 
 
Binding 
energy 
(kcal/mol) 
 
Inhibition 
constant 
(ki) (µm) 
ATP -1.68 - -2.34 - -3.51 - 
Derrubone -7.20 5.31 -7.53 2.40 -6.67 12.96 
Novobiocin -5.03 205.3 -7.00 7.34 -5.79 52.76 
Clorobiocin -6.59 14.72 -6.32 23.28 -6.15 31.15 
EGCG -5.52 90.20 -5.65 72.16 -5.13 174.35 
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LigPlot+ v.1.4.5 analysis, it was observed that Derrubone (with the best binding energy) also 
interacts with Leu 665 and Leu 666 residues of CTD (fig. 7) similar to ATP and Novobiocin.  
 
 
Figure 7. Hsp90α CTD and Derrubone interacting residues. 
4.4 ADME and Toxicity studies of existing drugs and newly developed Analogues using 
Discovery Studio 4.0. 
In the present work, the ADME and toxicity profiles of various NTD, CTD blocking drugs 
including Derrubone and its 30 designed Analogues were performed using Discovery studio 
4.0 to determine a potent inhibitor which has the recommended properties as required for 
crossing BBB and treating brain maladies like AD. For comparative studies, various properties 
such as molecular weight, lipophilicity (AlogP), polar surface area (PSA), rotatable bonds, 
hydrogen bond donors and acceptors were calculated for each analogue and the existing drugs 
(Table 2). Results obtained from TOPKAT studies showed that among the existing drugs 
Derrubone has the best AlogP value while the others have either low or very high AlogP value 
as compared to the recommended value. It also has favourable PSA, number of rotatable bonds, 
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hydrogen bond donors and acceptors. Hence, it can be observed from this analysis that 
Derrubone is best for its use as a CNS drug. Additionally, when TOPKAT studies of Derrubone 
and its 30 analogues were carried out, it was observed that Analogue 1, Analogue 2, Analogue 
3, Analogue 6, Analogue 7, Analogue 8, Analogue 9, Analogue 10 and Analogue 26 have 
improved lipophilicity than Derrubone, while keeping its Molecular weight, PSA, number of 
rotatable bonds, hydrogen bond donors and acceptors within the recommended range as 
required, for being a potent CNS drug [Table 2]. The structures of the above mentioned nine 
analogues are shown in (fig. 8) and the alterations made in the chemical structure of Derrubone 
to prepare these analogues have been encircled in the structure.       
Table 2 ADME properties of 30 analogues prepared. 
 
 
INHIBITOR 
 
MOLECULAR 
WEIGHT 
(<450) 
 
AlogP 
(<5) 
 
Polar 
Surface 
Area 
(PSA) 
(<60-90 
Aº2) 
 
ROTATABLE 
BONDS 
 
(<8) 
 
HYDROGEN 
BOND 
ACCEPTORS 
(<7) 
 
HYDROGEN 
BOND 
DONORS 
(<3) 
Derrubone 366 4.007 85.122 3 6 2 
Clorobiocin 697 5.034 185.22 10 11 5 
Novobiocin 612 3.459 196.16 9 11 5 
EGCG 458 3.096 197.37 4 11 6 
Geldanamycin 560 2.364 163.43 5 9 3 
17AAG 585 2.534 166.28 7 9 4 
Analogue 1 354 4.005 89.13 4 6 2 
Analogue 2 288 4.119 70.67 4 4 2 
Analogue 3 302 4.575 70.67 5 4 2 
Analogue 4 356 0.639 141.12 3 8 4 
Analogue 5 370 2.041 115.37 4 8 1 
Analogue 6 380 4.233 78.13 4 6 1 
Analogue 7 394 4.581 78.13 5 6 1 
Analogue 8 380 4.233 78.13 4 6 1 
Analogue 9 276 4.117 70.67 5 4 2 
Analogue 10 408 4.807 67.13 6 6 0 
Analogue 11 274 3.663 70.67 3 4 2 
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Analogue 12 290 2.437 90.91 4 5 3 
Analogue 13 303 2.597 82.70 5 5 3 
Analogue 14 317 3.115 73.91 5 5 2 
Analogue 15 318 2.611 96.97 5 6 2 
Analogue 16 342 1.847 109.37 3 7 3 
Analogue 17 356 1.815 126.32 3 8 3 
Analogue 18 341 1.577 115.105 3 7 3 
Analogue 19 355 2.009 101.23 4 7 3 
Analogue 20 369 2.545 92,37 4 7 2 
Analogue 21 354 1.915 106.20 3 7 2 
Analogue 22 304 2.345 107.81 4 6 3 
Analogue 23 289 2.147 96.87 4 5 3 
Analogue 24 304 1.259 122.81 4 6 4 
Analogue 25 302 2.485 87.71 4 5 2 
Analogue 26 394 4.481 78.13 5 6 1 
Analogue 27 264 -0.282 122.72 4 6 4 
Analogue 28 277 2.146 96.96 5 5 3 
Analogue 29 277 2.146 96.76 5 5 3 
Analogue 30 410 3.901 87.36 6 7 1 
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Figure 8. Structures of best nine analogues developed. 
Among the newly designed analogues, nine of these were found to be better than Derrubone 
from the analysis of the results obtained from TOPKAT studies and were selected for further 
studies. Furthermore, the Extensible Toxicity Protocol was used to evaluate several other 
properties of the selected analogues including Derrubone, such as aerobic biodegradability, 
AMES mutagenicity, Skin irritancy and Rodent Carcinogenicity. The observations from these 
studies are tabulated in Table 3. On analyzing these results it can be observed that while most 
of the analogues show aerobic biodegradability, Analogue 9 shows resistance towards 
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biodegradation. All the analogues are evidently non-mutagen and non- carcinogen in nature, 
while a few mild levels of skin irritation was observed. 
Table 3. Toxicity profile of various selected designed analogues. 
 
       Inhibitor 
 
Aerobic 
biodegradability 
 
AMES 
mutagenicity 
 
Skin irritancy 
 
Rodent Carcinogenicity 
Derrubone Degradable Non-Mutagen Non-Irritant Non-Carcinogen 
Analogue 1 Degradable Non-Mutagen Non-Irritant Non-Carcinogen 
Analogue 2 Degradable Non-Mutagen Non-Irritant Non-Carcinogen 
Analogue 3 Degradable Non-Mutagen Irritant Non-Carcinogen 
Analogue 6 Degradable Non-Mutagen Irritant Non-Carcinogen 
Analogue 7 Degradable Non-Mutagen Non-Irritant Non-Carcinogen 
Analogue 8 Degradable Non-Mutagen Irritant Non-Carcinogen 
Analogue 9 Non-Degradable Non-Mutagen Non-Irritant Non-Carcinogen 
Analogue 10 Degradable Non-Mutagen Non-Irritant Non-Carcinogen 
Analogue 26 Degradable Non-mutagen Non-Irritant Non-Carcinogen 
 
4.5 Validation of recognized ATP binding sites and comparison of our designed 
Derrubone analogues with the analogues synthesized experimentally  
Blagg and co-workers performed a set of experiments for the synthesis of Derrubone and 
related analogues to elucidate the Structure-Activity Relationships through the evaluation 
against colon and breast cancer cell lines [42].  They also performed anti-proliferative tests on 
the cell lines and summarized that their two analogues (BDA1 and BDA2 as denoted in this 
paper) showed better Hsp90 client protein-degradation activity than Derrubone (fig. 9). BDA1 
was prepared by transposing its prenyl side chain from 6th to 8th position of the isoflavon core 
and BDA2 was prepared by substituting with dichlorophenyl at 3rd position in the isoflavon 
backbone. It was also observed from their experiment that these drug candidates showed a 
decrease in Her2 and Raf levels, as these two proteins depend upon Hsp90 [42].  
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Figure 9. Analogues prepared at Blagg's Laboratory (BDA1 and BDA2)  
In our current work, the results obtained by Blagg et al. were validated by performing 
molecular docking experiments and ADME studies of the two best analogues of Derrubone 
(out of 10 analogues tested) in comparison with Derrubone. The results of TOPKAT studies 
which are tabulated in Table 4 showed that the AlogP value of BDA1 is the same as that of 
Derrubone and BDA2 has higher AlogP (>5) which is not in the recommended range. Further, 
from molecular docking experiments using Autodock 4.0, it was observed that BDA1 (-7.10 
kcal/mol) and BDA2 (-7.04 kcal/mol) have better binding affinity than Derrubone (-6.67 
kcal/mol) at Leu 694 indicating that these analogues have a higher possibility of binding to this 
site rather than to other previously recognized sites.ie. Leu 665 and Leu 666 (Table 5). Docking 
results at Leu 694 also showed that the inhibition constant of both the analogues were found to 
be upto three times lesser than Derrubone. This result may indicate that Leu 694 may be the 
natural binding pocket as it is present in the largest cavity of Hsp90α, for Analogue BDA1 and 
BDA2 given its high binding energy at this site. 
It can be validated from these experiments that BDA1 and BDA2 experiences steric hindrance 
at site Leu 665 and Leu 666, hence, the analogues do not show good binding affinity at these 
sites as compared to Leu 694. As our recognized ATP binding site i.e. Leu 694 has been 
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validated from experimental results therefore this site could possibly be the ATP binding site 
and could be further used to perform molecular docking experiments of our designed analogue 
to obtain a potent candidate for AD treatment. 
Table 4.  ADME properties of Blagg analogues. 
 
Table 5. Docking energies and inhibition constant of Blagg analogues against Hsp90α. 
 
4.6 Molecular Docking of Hsp90α with Derrubone and selective Analogues 
The molecular docking studies were carried out using Autodock 4.0 to attain the binding 
affinitiesof various analogues against Hsp90α CTD. The experimentation was carried out by 
docking nine previously selected analogues on previously recognized ATP binding residue of 
INHIBITOR MOLECULAR 
WEIGHT 
 
(<450) 
AlogP 
 
 
(<5) 
Polar 
Surface 
Area (PSA) 
(<60-90 
Aº2) 
ROTATABLE 
BONDS 
 
(<8) 
HYDROGEN 
BOND 
ACCEPTORS 
(<7) 
HYDROGEN 
BOND 
DONORS 
(<3) 
Derrubone 366 4.007 85.122 3 6 2 
BDA1 366 4.007 89.130 3 6 2 
BDA2 391 5.568 70.700 3 4 2 
 
LIGAND 
 
TARGET 
 
LEUCINE 665 
 
LEUCINE 666 
 
LEUCINE 694 
 
 
Drug/ 
Analogues 
 
 
 
 
 
 
 
 
Hsp90α CTD 
 
Binding 
energy 
(kcal/mol) 
 
Inhibition 
constant 
(ki) (µm) 
 
Binding 
energy 
(kcal/mol) 
 
Inhibition 
constant 
(ki) (µm) 
 
Binding 
energy 
(kcal/mol) 
 
Inhibition 
constant 
(ki) (µm) 
Derrubone -7.20 5.31 -7.53 2.40 -6.67 12.96 
BDA1 -5.04 203.71 -7.35 4.13 -7.10 6.23 
BDA2 6.56 15.61 -6.43 19.34 -7.04 6.89 
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Hsp90α CTD i.e. Leu 694, respectively. The binding energies and the inhibition constant values 
obtained from the investigation are tabulated in Table 6. The results obtained from the 
experiment show that Analogue 26 has better binding energy than Derrubone at previously 
recognized site: Leu 694 (-10.20 kcal/mol) with improved ki value 0.036 µM. 
 
Table 6. Docking results of Derrubone and designed analogues against Hsp90α. 
LIGAND TARGET             LEUCINE 694 
Drug/ 
Analogues 
 
 
 
 
 
 
 
 
 
 
Hsp90α 
Binding 
energy 
(kcal/mol) 
Inhibition 
constant 
(ki) (µM) 
Derrubone -6.67 12.96 
Analogue 1 -6.65 13.25 
Analogue 2 -6.57 15.33 
Analogue 3 -5.76 59.65 
Analogue 6 -6.51 17.02 
Analogue 7 -6.97 7.80 
Analogue 8 -6.28 24.95 
Analogue 9 -5.25 89.64 
Analogue 10 -7.48 3.27 
Analogue26 -10.16 0.036 
 
Furthermore, when the results obtained from ADME and toxicity studies and molecular 
docking experiments of Derrubone, BDA1and BDA2 with Hsp90α CTD, were compared to 
the results obtained of Analogue 26, it was observed that the AlogP, binding affinity as well as 
the ki of Analogue 26 was better than that of Derrubone and Blagg’s analogues. The results 
obtained showed that Analogue 10 could be a potential drug candidate for Hsp90α inhibition 
as compared to Derrubone, BDA1 and BDA2. 
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4.7 ADME Plots 
As observed from the plot (fig. 10 and fig. 11), it can be seen that Derrubone, BDA1and BDA2 
fall beyond the BBB-95 but within BBB-99 ellipse whereas comparatively Analogue 26 falls 
on the margin of BBB-95 plot. This shows that the former may not be well suited for CNS 
administration due to their lack of BBB absorption capability. It also shows that Analogue 26 
falls into the category of those drugs that are a part of 99% of well-absorbed drugs into the 
blood brain barrier. It can also be observed from the plot that BDA2 falls marginally on 
absorption-95 plot indicating that this drug may be less likely to be suited for sufficient 
intestinal absorption; whereas the remaining three drugs studied show easy intestinal 
absorption as indicated by their position within absorption-95 and absortion-99 ellipses in the 
graph. 
               
Figure 10. BBB penetration and Human intestinal absorption for:  A. Derrubone  B. BDA1 
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Figure 11. BBB penetration and Human intestinal absorption for:  A. BDA2  B. Analogue 26 
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CHAPTER 4 
CONCLUSION 
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4.1 CONCLUSION  
From the present investigation it was concluded that the recognized sites i.e. Leu 665, Leu 667 
and Leu 694 could be possible ATP binding sites that are present in the CTD of Hsp90α. The 
docking experiments which were performed between the various existing drugs and Hsp90α at 
the three recognized ATP binding sites revealed that Derrubone has the lowest binding energy 
with minimum value of inhibition constant. It was also observed that at Leu 666 Derrubone 
gave the best binding affinity (-7.53 kcal/mol) and inhibition constant (2.40µM).  The 
recognition of Derrubone as Hsp90α inhibitor gives a natural product which could be used 
further for obtaining a more specific novel inhibitor. 
 
To resolve the problems associated with various NTD and CTD blocking drugs including 
Derrubone, in our present work 30 analogues of Derrubone which can bind to the previously 
determined ATP binding sites of Hsp90α CTD i.e. Leu 665, Leu 666 and Leu, were prepared. 
The ADME and toxicity profiles of the existing drugs and analogues were performed using 
Discovery studio 4.0 to determine a potent inhibitor which has the recommended properties as 
required for crossing BBB and treating brain maladies such as AD. From the studies it was 
observed that Analogue 1, Analogue 2, Analogue 3, Analogue 6, Analogue 7, Analogue 8, 
Analogue 9, Analogue 10 and Analogue 26 have improved lipophilicity as compared to 
Derrubone and other existing drugs while keeping its molecular weight, number of rotatable 
bonds, hydrogen bond donor and acceptors within the recommended range as required to be 
classified as CNS drug. From Extensible Toxicity Protocol studies it was indicated that these 
analogues are clearly non-mutagen and non- carcinogen in nature, while a few mild levels of 
skin irritation was observed.  
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In our present communication, the experimental results obtained from Blagg et al. laboratory 
were validated by performing molecular docking experiments and ADME studies of the two 
analogues in comparison with Derrubone. The TOPKAT studies showed that the AlogP value 
of BDA1 is the same as that of Derrubone and BDA2 has higher AlogP (>5) which is not in 
the recommended range. Further, from molecular docking it was observed that BDA1(-7.10 
kcal/mol) and BDA2(-7.04 kcal/mol) have better binding affinity than Derrubone (-6.67 
kcal/mol) at Leu 694 of the Hsp-90 CTD, indicating that these analogues have a higher 
possibility of binding to this site rather than to other previously recognized sites i.e. Leu 665 
and Leu 666. Docking results at Leu 694 also showed that the inhibition constant of both the 
analogues were found to be three times lesser than Derrubone. It can be concluded from this 
result that Leu 694 may be the natural binding pocket for BDA1 and BDA2 given its high 
binding energy at this site. Hence, our previously determined ATP binding site Leu 694 had 
been validated from the experimental results. However, since BDA1and BDA2 were originally 
tested upon cancer cell lines and the properties of these do not closely resemble to CNS drugs 
it would be irrelevant to further analyse them for the possibilities of AD treatment.  
Further, the study was carried out by docking nine previously selected analogues with 
previously recognized and validated ATP binding residue Leu 694 of Hsp90α CTD indicated 
that Analogue 26 (-10.20 kcal/mol) has better binding energy than Derrubone with improved 
ki value 0.036 µM. It can be concluded from the ADME graph plotted between AlogP98 vs 
PSA that Derrubone, BDA1and BDA2 fall beyond the BBB-95 but within BBB-99 ellipse, 
whereas Analogue 26 falls on the margin of BBB-95 plot. This indicates that the former may 
not be well suited for CNS administration due to their lack of BBB absorption capability. It 
also reveals that Analogue 26 falls into the category of those drugs that are a part of 99% of 
well-absorbed drugs into the blood brain barrier. It can be concluded that the Analogue 26 may 
be well suited for CNS administration due to its BBB absorption capability. As it was also 
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observed from the plot that BDA2 falls marginally on absorption-95 plot indicating that this 
drug may only be marginally suited for intestinal absorption in a small quantity. The remaining 
three drugs studied show easy intestinal absorption as indicated by their position within 
absorption-95 and absortion-99 ellipses in the graph. Hence, it can be concluded that Analogue 
26 could possibly be used for performing in-vitro and in-vivo experiments for its approval as 
a potent AD treatment drug. The establishment of ATP binding site in CTD and determining 
the best inhibitor for Hsp90α could further lead to the effective blockage of Hsp90α which 
would subsequently result in the degradation of Tau proteins for the treatment of Alzheimer’s 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
REFERENCES 
1. Khalid S and Paul S. Identifying a C-terminal ATP binding sites-based novel Hsp90-
Inhibitor in silico: A plausible therapeutic approach in Alzheimer’s disease. Med 
Hypotheses Medical Hypotheses 2014; 83(1): 39-46. 
2. Drachman D. Do we have brain to spare?  Neurology. 2005; 64 (12): 2004–5. 
3. Dale HH. Transmission of Nerve Impulses. Br Med J. 1951; 2(4736): 893 
4. Khann M, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease: Report 
of the NINCDS−and Human Services Task Force on Alzheimer's Disease ADRDA 
Work Group* under the auspices of Department of Health Guy. Neurology. 1984; 34: 
939. 
5. Auguste D, Maurer K, Volk S, Gerbaldo H. Alzheimer’s disease. 1997; 349. 
6. Rainulf A. Stelzma, H. Norman Schnitzlein, and F. Reed Murllagh. An English 
I’ranslation of Alzheimer’s 1907 Paper, “ijber eine eigenartige Erlranliung der 
Hirnrinde”. Clinical Anatomy. 1995; 8:429-431  
7. Maurer K, Volk S, Gerbaldo H.  Auguste D and Alzheimer’s disease. 1997; 349 
8. Mendez MF. The Accurate Diagnosis of Early-onset Dementia”, International Journal 
of Psychiatry Medicine. 2006; 36(4) :401–412. 
9. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural Correlates of Alzheimer's 
Disease and Mild Cognitive Impairment: A Systematic and Quantitative Meta-Analysis 
involving 1,351 Patients. NeuroImage. 2009; 47(4): 1196–120. 
10. Khann Mc, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease: Report 
of the NINCDS−and Human Services Task Force on Alzheimer's Disease  ADRDA 
Work Group* under the auspices of Department of Health Guy. Neurology. 1984; 34: 
939. 
 
 
51 
 
11. Stahl SM. The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 2: 
Illustrating Their Mechanisms of Action. J Clin Psychiatry. 2000; 61(11): 813–814. 
12. Birks J. Cholinesterase Inhibitors for Alzheimer's Disease". In Birks, 
Jacqueline. Cochrane Database Syst Rev. 2006; (1): CD005593. 
13. Tariot PN, Farlow MR, Grossberg GT. Memantine treatment in patients with moderate 
to severe Alzheimer’s disease already receiving donepezil a randomized controlled 
trial. JAMA. 2004; 291: 327-324. 
14. Reisberg B, Doody R, Stoffler A. Memantine in moderate-to-severe Alzheimer’s 
disease. N Engl JMed. 2003; 348: 1333–1341. 
15. Wagner G, Icks A, Abholz H-H, Schröder-Bernhardi D, Rathmann W, Kostev K. 
Antihypertensive treatment and risk of dementia: a retrospective database study. Int J 
Clin Pharmacol Ther. 2012; 50: 195–201. 
16. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G. Amitriptyline is a TrkA 
and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent 
neurotrophic activity.  Chem Biol. 2009; 16: 644–656.  
17. Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. 
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the 
preclinical data. J Neuropsychiatry Clin Neurosci. 2010; 22: 8–18. 
18. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A. Serotonin 
signaling is associated with lower amyloid-â levels and plaques in transgenic mice and 
humans. Proc Natl Acad Sci USA. 2011; 108: 14968–14973. 
19. Youdim MBH,  Am OB, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M. 
Rasagiline: neurodegeneration,neuroprotection, and mitochondrial permeability 
transition. J Neurosci Res 2005; 79: 172–179. 
 
 
52 
 
20. Youdim MBH. The path from anti Parkinson drug selegiline and rasagiline to 
multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr 
Alzheimer Res. 2006; 3: 541–550. 
21. Chen Y, Zhou K, Wang R, Liu Y, Kwak Y-D, Ma T. Antidiabetic drug metformin 
(Glucophage®) increases biogenesis of Alzheimer’s amyloid peptides via up-
regulating BACE1 transcription.  Proc Natl Acad Sci USA. 2009; 106: 3907–3912. 
22. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates 
neuronal insulin resistance and Alzheimer’s-like changes.  Neuropharmacology. 2011; 
60: 910–920. 
23. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, et al. Chaperones 
increase association of Tau protein with microtubules. ProcNatlAcadSci U S A. 2003; 
100: 721–6. 
24. Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, et al. A non-toxic 
Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med ChemLett. 
2007; 17: 1984–90. 
25. Amolins MW, Blagg BS. Natural product inhibitors of Hsp90: potential leadsfor drug 
discovery. Mini Rev Med Chem. 2009; 9: 140–52. 
26. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation 
of geldanamycin as an antitumor agent. Cancer ChemotherPharmacol. 1995; 36: 305–
15. 
27. Schulte TW, Neckers LM. The benzoquinoneansamycin 17-allylamino-17- 
demethoxygeldanamycin binds to HSP90 and shares important biologicactivities with 
geldanamycin. Cancer ChemotherPharmacol. 1998; 42: 273–9. 
28. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, et al. Design, synthesis, and 
biological evaluation of hydroquinone derivatives of 17-amino-17- 
 
 
53 
 
demethoxygeldanamycin as potent, water soluble inhibitors of Hsp90. J Med Chem. 
2006; 49: 4606–15. 
29. Palermo CM, Westlake CA, Gasiewicz TA. Epigallocatechingallate inhibits aryl 
hydrocarbon receptor gene transcription through an indirect mechanism involving 
binding to a 90 kDa heat shock protein. Biochemistry. 2005; 44: 5041–52. 
30. Marcu MG, Schulte TW, Neekers L. Novobiocin and related coumarins and depletion 
of heat shock protein 90-dependent signaling proteins. J NatlCancerInst. 2000; 92: 242–
8. 
31. Palermo CM, Hernando JI, Dertinger SD, Kende AS, Gasiewicz TA. Identification of 
potential aryl hydrocarbon receptor antagonists in green tea. ChemResToxicol. 2003; 
16: 865–72. 
32. East AJ, Ollis WD, Wheeler RE. Natural occurrence of 3-aryl-4-hydroxycoumarins. 
Part I. Phytochemical examination of Derris robusta (roxb) benth. J ChemSoc 1969; 3: 
365–73. 
33. Hadden MK, Galam L, Gestwicki JE, Matts RL, Blagg BSJ. Derrubone, aninhibitor of 
the Hsp90 protein folding machinery. J Nat Prod. 2007; 70: 2014–8. 
34. East AJ, Ollis WD, Wheeler RE. Natural occurrence of 3-aryl-4-hydroxycoumarins. 
Part I. Phytochemical examination of Derris robusta(roxb.) benth. J. Chem. Soc. 1969; 
C 3: 365–74. 
35. Shoji M,  Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD. Production of 
the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992; 
258: 126-9. 
36. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of beta-amyloid in 
the secretory pathway in neuronal and nonneuronal cell. Proc. Natl. Acad. Sci. U.S.A. 
1993; 90: 2092-6. 
 
 
54 
 
37. Goedert M, Spillantini MG, Crowther RA. Tau Proteins and Neurofibrillary 
Degeneration. Brain Pathol. 1991; 1(4): 279–86. 
38. Chun W, Johnson GV. The Role of Tau Phosphorylation and Cleavage in Neuronal 
Cell Death. Front Biosci. 2007; 12: 733–56. 
39. Kosik KS, Shimura H. Phosphorylated Tau and the neurodegenerative foldopathies. 
BiochimBiophysActa. 2005; 1739: 298–310. 
40.  Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP–Hsc70 complex ubiquitinates 
phosphorylated Tau and enhances cell survival. J BiolChem. 2004; 279: 4869–76. 
41. Concannon CG, Gorman AM, Samali A. On the role of Hsp27 in regulating apoptosis. 
Apoptosis. 2003; 8: 61–70. 
42. Salminen A, Ojala J, Kaarniranta K, Hiltunen M, Soininen H. Hsp90 regulates Tau 
pathology through co-chaperone complexes in Alzheimer’s disease. ProgNeurobiol. 
2011; 93: 99–110. 
43. Terasawa K, Minami M, Minami Y.Constantly updated knowledge of Hsp90.  J 
Biochem. 2005; 137: 443–447  
44. Issacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer 
therapeutics.  Cancer Cell. 2003; 3: 213–217.  
45. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L.17AAG: low 
target binding affinity and potent cell activity--finding an explanation.Mol Cancer Ther. 
2003; 2: 123–129. 
46. Salminen A, Ojala J, Kaarniranta K, Hiltunen M, Soininen H. Hsp90 regulates Tau 
pathology through co-chaperone complexes in Alzheimer’s disease. ProgNeurobiol. 
2011; 93: 99–110. 
47. Soti C, Racz A, Csermely P. A nucleotide-dependent molecular switch controls ATP 
binding at the C-terminal domain of Hsp90. J BiolChem2001; 277: 7066–75. 
 
 
55 
 
48. Yun BG, Huang W, Leach N, Hartson SD, Matts RL. Novobiocin induces a distinct 
conformation of Hsp90 and alters Hsp90-cochaperone–client interactions. 
Biochemistry. 2004; 43: 8217–29. 
49. Allan RK, Mok D, Ward BK, Ratajczak T. Modulation of chaperone function and 
cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence 
that coumarin antibiotics disrupt Hsp90 dimerization. J BiolChem. 2006; 281: 7161–
71. 
50. Pratt WB, Morishima Y, Peng HM, Osawa Y. Proposal for a role of the Hsp90/ Hsp70-
based chaperone machinery in making triage decisions when proteins undergo 
oxidative and toxic damage. ExpBiol Med. (Maywood) 2010; 235: 278–89. 
51. Csermely P, Kajtar J, Hollosi M, Jalsovszky G, Holly S, Kahn CR, et al. ATP induces 
a conformational change of the 90-kDa heat shock protein (Hsp90). JBiolChem. 1993; 
268: 1901–7. 
52.  Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, et al. Chaperones 
increase association of Tau protein with microtubules. ProcNatlAcadSci U S A. 2003; 
100: 721–6. 
53. Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, et al. A non-toxic 
Hsp90 inhibitor protects neurons from Abeta-induced toxicity. BioorgMedChemLett. 
2007; 17: 1984–90. 
54. Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BSJ.Hsp90 
inhibitors identified from a library of novobiocinanalogues J Am ChemSoc. 2005; 127: 
12778–9. 
55.  Zhang H, Burrows F.Targeting multiple signal transduction pathways through 
inhibition of Hsp90. J Mol Med. 2004; 82: 488. 
 
 
56 
 
56. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 
17-(allylamino)- 7-demethoxygeldanamycin (NSC 330507) by murine and human 
hepatic preparations. Cancer Res. 1998; 58: 2385–96. 
57. Prodromou C, Panaretou B, Chohan S, Siligardi G, O’Brien R, Ladbury JE, et al. The 
ATPase cycle of Hsp90 drives a molecular ‘clamp’ via transient dimerization of the N-
terminal domains. EMBO J. 2000; 19: 4383–92.  
58. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation 
of geldanamycin as an antitumor agent. Cancer ChemotherPharmacol. 1995; 36: 305–
15. 
59. Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, et al. 
Preclinical toxicity of a geldanamycinanalog, 17-(dimethylaminoethylamino)- 17-
demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinicalrelevance. 
Cancer ChemotherPharmacol. 2005; 56: 637–47. 
60. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL. Metabolism of 
17-(allylamino)- 7-demethoxygeldanamycin (NSC 330507) by murine andhuman 
hepatic preparations. Cancer Res. 1998; 58: 2385–96. 
61. Marcu MG, Schulte TW, Neekers L. Novobiocin and related coumarins and depletion 
of heat shock protein 90-dependent signaling proteins. J NatlCancerInst. 2000; 92: 242–
8. 
62. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers L. The heat shock protein 90 
antagonist novobiocin interacts with a previously unrecognized ATP-binding domain 
in the carboxyl terminus of the chaperone. M.J. Biol. Chem. 2000; 275: 37181–6. 
63. Sgobba M, Forestiero R, Degliesposti G, Rastelli G. Exploring the binding site of C-
terminal Hsp90 inhibitors. J Chem Inf Model 2010; 50: 1522–8. 
 
 
57 
 
64. Shiau AK, Harris SF, Southworth DR, Agard DA. Structural analysis of E. coli Hsp90 
reveals dramatic nuclotide-dependent conformational rearrangements. Cell 2006; 127: 
329–40. 
65. Matts RL, Dixit A, Peterson LB, Sun L. Elucidation of the Hsp90 C-terminal inhibitor 
binding site. ACS Chem Biol 2011; 6: 800–7. 
66. Pajouhesh H and Lenz GR. Medicinal Chemical Properties of Successful Central 
NervousSystem Drugs. The American Society for Experimental NeuroTherapeutics, 
Inc. 2005; 2: 541–53. 
67. Dennis M. Absorption processes, In: Comprehensive medicinal chemistry. Oxford,UK: 
Pergamon. 1990; 5: 1–44.  
68. Kelder J, Grootenhuis PDJ, Bayada DM, Delbressine LPC, Ploemen J-P. Polar 
molecular surface as a dominating determinant for oral absorption and brain penetration 
of drugs. Pharm Res. 1999; 16: 1514–19. 
69. Van de Waterbeemd H, Camenish G, Folkers G, Chretien JR Raevsky OA. Estimation 
of blood-brain barrier crossing of drugs using molecular size and shape and H-bonding 
characteristics. JDrug Target. 1998; 6: 151–165. 
70. Mohammad S. Alavijeh, Mansoor Chishty, M. Zeeshan Qaiser, and Alan M. Palmer. 
Drug Metabolism and Pharmacokinetics, the Blood-Brain Barrier, and Central Nervous 
System Drug Discovery. The American Society for Experimental NeuroTherapeutics, 
Inc. 2005; 2: 554–571.  
71. Hastings JM, Hadden MK, Blagg BSJ. Synthesis and evaluation of Derrubone andselect 
analogues. J Org Chem. 2008; 73: 369–73. 
72. Chauhan JS, Mishra NK, Raghava GPS. Identification of ATP binding residues of a 
protein from its primary sequence. BMC Bioinformatics 2009; 10: 434. 
 
 
 
58 
 
Publications 
 Khalid S and Paul S. Identifying C-terminal ATP binding sites-based novel Hsp90-
Inhibitor in-silico: A plausible therapeutic approach in Alzheimer’s disease. 
Medical Hypotheses 2014; 83(1): 39-46. 
 
 In silico Design of novel Derrubone analogues Hsp90-inhibitor for Tau protein 
degradation: A therapeutic approach in Alzheimer’s disease. (Under preparation)   
 
 
